Evogene (EVGN) to Release Quarterly Earnings on Wednesday

Evogene (NASDAQ:EVGN) is scheduled to issue its 09/30/2023 quarterly earnings data before the market opens on Wednesday, November 15th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, August 17th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.77 million. Evogene had a negative return on equity of 68.84% and a negative net margin of 943.25%. During the same period last year, the firm earned ($0.21) earnings per share. On average, analysts expect Evogene to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evogene Stock Up 2.3 %

NASDAQ EVGN opened at $0.57 on Monday. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44. The business has a 50-day moving average price of $0.59 and a 200-day moving average price of $0.75. The firm has a market cap of $23.30 million, a price-to-earnings ratio of -1.03 and a beta of 1.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EVGN. BNP Paribas Arbitrage SNC raised its stake in Evogene by 265.4% during the second quarter. BNP Paribas Arbitrage SNC now owns 26,700 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 19,393 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Evogene during the 1st quarter valued at about $48,000. Renaissance Technologies LLC lifted its holdings in shares of Evogene by 31.8% in the 1st quarter. Renaissance Technologies LLC now owns 118,193 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 28,493 shares during the last quarter. Vident Investment Advisory LLC grew its position in Evogene by 68.5% in the first quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 34,082 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Evogene by 49.7% during the first quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 67,867 shares during the last quarter. 1.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EVGN has been the subject of several recent analyst reports. Lake Street Capital upped their price target on Evogene from $2.00 to $3.00 and gave the stock a “buy” rating in a research note on Friday, August 18th. StockNews.com raised shares of Evogene to a “sell” rating in a research note on Thursday, October 26th. Roth Mkm lifted their price target on shares of Evogene from $1.00 to $6.00 and gave the company a “buy” rating in a report on Friday, July 21st. Finally, Alliance Global Partners assumed coverage on shares of Evogene in a report on Monday, October 2nd. They set a “buy” rating and a $1.85 price objective for the company.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.